AR063138A1 - Comprimidos pediatricos de capecitabina - Google Patents

Comprimidos pediatricos de capecitabina

Info

Publication number
AR063138A1
AR063138A1 ARP070104409A ARP070104409A AR063138A1 AR 063138 A1 AR063138 A1 AR 063138A1 AR P070104409 A ARP070104409 A AR P070104409A AR P070104409 A ARP070104409 A AR P070104409A AR 063138 A1 AR063138 A1 AR 063138A1
Authority
AR
Argentina
Prior art keywords
capecitabine
tablet
pharmaburst
cobb
crospovidone
Prior art date
Application number
ARP070104409A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR063138A1 publication Critical patent/AR063138A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

Se proporciona una composicion farmacéutica recubierta por una película que comprende 5'-desoxi-5-fluoro-N-[(pentiloxi)-carbonil]-citidina (capecitabina) y al menos un disgregante seleccionado del grupo que comprende crospovidona (tamano de partícula <15-400 micrometros), croscarmelosa sodica, glicolato de almidon de maíz, hidroxipropilcelulosa poco sustituida, Pharmaburst C o cualquier combinacion de estos, junto con otros excipientes farmacéuticamente aceptables para formar un comprimido que se disgrega rápidamente. Este comprimido se disgrega en agua a 37°C en un aparato de disgregacion USP en menos de 2 minutos, preferiblemente 1 minuto y posee una dureza de 8-13 unidades de fuerza Cobb.
ARP070104409A 2006-10-06 2007-10-04 Comprimidos pediatricos de capecitabina AR063138A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85017406P 2006-10-06 2006-10-06
US95155707P 2007-07-24 2007-07-24

Publications (1)

Publication Number Publication Date
AR063138A1 true AR063138A1 (es) 2008-12-30

Family

ID=39186803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104409A AR063138A1 (es) 2006-10-06 2007-10-04 Comprimidos pediatricos de capecitabina

Country Status (31)

Country Link
US (2) US20080085310A1 (es)
EP (1) EP2073791B1 (es)
JP (1) JP5330248B2 (es)
KR (1) KR101177730B1 (es)
CN (1) CN101522168B (es)
AR (1) AR063138A1 (es)
AT (1) ATE492267T1 (es)
AU (1) AU2007304293A1 (es)
BR (1) BRPI0719241A2 (es)
CA (1) CA2664922C (es)
CL (1) CL2007002875A1 (es)
CO (1) CO6150122A2 (es)
CR (1) CR10668A (es)
CY (1) CY1111223T1 (es)
DE (1) DE602007011475D1 (es)
DK (1) DK2073791T3 (es)
HK (1) HK1135905A1 (es)
HR (1) HRP20110113T1 (es)
IL (1) IL197767A0 (es)
MA (1) MA30779B1 (es)
MX (1) MX2009003317A (es)
MY (1) MY145637A (es)
NO (1) NO20090980L (es)
NZ (1) NZ575280A (es)
PE (1) PE20081106A1 (es)
PL (1) PL2073791T3 (es)
PT (1) PT2073791E (es)
RU (1) RU2455979C2 (es)
SI (1) SI2073791T1 (es)
TW (1) TW200825096A (es)
WO (1) WO2008040665A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TWI455733B (zh) * 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
CN103156877B (zh) * 2011-12-13 2015-11-25 深圳海王药业有限公司 一种卡培他滨速释微丸及其制备方法
CN102988320B (zh) * 2012-12-13 2014-04-16 哈药集团技术中心 一种卡培他滨分散片及其制备方法
CN104739800A (zh) * 2015-02-03 2015-07-01 吉林修正药业新药开发有限公司 一种卡培他滨片组合物及其制备方法
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
JP6866113B2 (ja) * 2016-11-01 2021-04-28 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
JP7170554B2 (ja) 2019-02-06 2022-11-14 ゼネラル株式会社 感熱転写媒体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
CA2322315C (en) * 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
RU2135169C1 (ru) * 1998-12-02 1999-08-27 Государственное предприятие Казанское производственное химико-фармацевтическое объединение "Татхимфармпрепараты" Противовоспалительное, болеутоляющее, жаропонижающее лекарственное средство и способ его получения
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
CA2403594A1 (en) * 2000-03-27 2002-09-18 Kyowa Hakko Kogyo Co., Ltd. Granules having good taking property
WO2002069934A1 (fr) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Préparations se délitant rapidement dans la bouche
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
DE102004028940A1 (de) * 2004-06-15 2006-01-12 Krka Tovarna Zdravil, D.D. Oral zerfallende pharmazeutische Zusammensetzung, die Risperidon enthält
DE112006000873T5 (de) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs

Also Published As

Publication number Publication date
CO6150122A2 (es) 2010-04-20
CY1111223T1 (el) 2015-06-11
HK1135905A1 (en) 2010-06-18
KR20090045948A (ko) 2009-05-08
KR101177730B1 (ko) 2012-09-07
MY145637A (en) 2012-03-15
US20080085310A1 (en) 2008-04-10
EP2073791B1 (en) 2010-12-22
NO20090980L (no) 2009-03-31
PL2073791T3 (pl) 2011-05-31
SI2073791T1 (sl) 2011-04-29
PE20081106A1 (es) 2008-09-17
JP5330248B2 (ja) 2013-10-30
US20150044287A1 (en) 2015-02-12
CN101522168A (zh) 2009-09-02
WO2008040665A3 (en) 2008-06-19
MA30779B1 (fr) 2009-10-01
CA2664922A1 (en) 2008-04-10
MX2009003317A (es) 2009-04-09
IL197767A0 (en) 2009-12-24
ATE492267T1 (de) 2011-01-15
JP2010505791A (ja) 2010-02-25
CL2007002875A1 (es) 2008-01-25
NZ575280A (en) 2012-03-30
EP2073791A2 (en) 2009-07-01
DK2073791T3 (da) 2011-01-31
RU2009116816A (ru) 2010-11-20
BRPI0719241A2 (pt) 2014-07-15
PT2073791E (pt) 2011-01-21
RU2455979C2 (ru) 2012-07-20
CN101522168B (zh) 2011-09-28
CR10668A (es) 2009-04-29
HRP20110113T1 (hr) 2011-03-31
AU2007304293A1 (en) 2008-04-10
TW200825096A (en) 2008-06-16
DE602007011475D1 (de) 2011-02-03
WO2008040665A2 (en) 2008-04-10
CA2664922C (en) 2015-06-30

Similar Documents

Publication Publication Date Title
AR063138A1 (es) Comprimidos pediatricos de capecitabina
WO2010069795A3 (en) Capecitabine rapidly disintegrating tablets
US20090186086A1 (en) Solid multilayer oral dosage forms
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
BRPI0414311A (pt) formas de dosagem de liberação controlada
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
HUP0401941A2 (hu) Protonpumpa inhibitort és savmegkötőket tartalmazó gyógyszerforma és eljárás az előállítására
PE20051127A1 (es) Comprimido multicapa de telmisartan y ramipril
EP1595538A3 (en) Modified release tamsulosin tablets
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
IL177243A0 (en) Extended release coated minitablets of venlafaxine hydrochloride
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
BR0117147A (pt) preparado de dosagem oral de desintegração instantánea
CN106029637A (zh) 新的组合物
JP5208729B2 (ja) 徐放性錠剤の製造方法
RU2006137329A (ru) Распадающиеся таблетки, содержащие ликарбазепин
Jadon et al. Taste masking of Lornoxicam by polymer carrier system and formulation of oral disintegrating tablets
Yunarto Optimasi formula tablet salut enterik natrium diklofenak dengan bahan penyalut kollicoat 30 D
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
ES2238497T3 (es) Granulado de ribavirina para la obtencion de comprimidos peliculados.
MX2009006873A (es) Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
Mahajan et al. An overview on Superdisintegrants
Jaidev et al. Development of alfuzosin gastro resistant prolonged release tablet and evaluate using HPLC
TH95087A (th) ยาเม็ดคาเพคซิตาบินสำหรับเด็ก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal